NAD(P)H:quinone oxidoreductase 1 (NQO1): Chemoprotection, bioactivation, gene regulation and genetic polymorphisms

Chemico-Biological Interactions

Volumn 129, Issue 1-2, 2000, Pages 77-97

  Ross, David ^a   Kepa, Jadwiga K ^a   Winski, Shannon L ^a   Beall, Howard D ^b   Anwar, Adil ^a   Siegel, David ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF MONTANA   (United States)

Author keywords

Antioxidant response element (ARE); Antitumor quinones; Gene regulation; NQO1 (NAD(P)H:quinone oxidoreductase 1); Polymorphisms; Quinone; Ubiquinone; Vitamin E

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; ANTINEOPLASTIC AGENT; BENZOQUINONE MUSTARD; DIAZIQUONE; MITOMYCIN C; PYRROLOBENZIMIDAZOLEQUINONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE) 1; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER SUSCEPTIBILITY; CATALYSIS; CYTOTOXICITY; DETOXIFICATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME MECHANISM; ENZYME SPECIFICITY; GENE CONTROL; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; REACTION ANALYSIS; SOLID TUMOR; TRANSCRIPTION REGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOTRANSFORMATION; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HUMANS; METABOLIC DETOXICATION, DRUG; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, GENETIC;

EID: 0034531564     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-2797(00)00199-X     Document Type: Article

References (155)

1. Soluble diaphorase in animal tissues
2. DT-diaphorase
3. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism
4. The three dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: Mechanism of the two electron reduction
5. Difference in the mechanism of quinone reduction by the NADH dehydrogenase and the NAD(P)H dehydrogenase (DT-diaphorase)
6. DT-diaphorase: Redox potential, steady-state, and rapid reaction studies
7. DT-diaphorase: Purification properties and function
8. Quinone reductases
9. On the mechanism of the Mn-induced neurotoxicity of dopamine: Prevention of quinone derived oxygen toxicity by DT-diaphorase and superoxide dismutase
10. Dinitropyrene nitroreductase activity of purified NAD(P)H:quinone oxidoreductase: Role in rat liver cytosol and induction by Aroclor-1254 pretreatment
11. A CB 1954 analog that is highly cytotoxic in human tumor cell lines
12. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1. 6. 99. 2.)
13. The differences in kinetics of rat and human DT-diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide)
14. Rat liver cytosolic azoreductase
15. Subunit functional studies of NAD(P)H:quinone oxidoreductase with a heterodimer approach
16. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study of the implication of oxidative stress in intact cells
17. The role of reductive and oxidative metabolism in the toxicity of mitoxantrone, adriamycin and menadione in human liver derived Hep G2 hepatoma cells
18. Metabolism of drugs in the eye. Menadione-dependent reduction of tertiary amine N-oxide by preparations from bovine ocular tissues
19. Detoxification ability and toxicity of quinones in mouse and human tumor cell lines used for anticancer drug screening
20. DT-diaphorase protects against menadione-induced oxidative stress
21. DT-diaphorase as a quinone reductase: A cellular control device against semiquinone and superoxide radical formation
22. 14C]menadione
23. Hepatic low-level chemiluminescence during redox cycling of menadione and the menadione-glutathione conjugate: Relation to glutathione and NAD(P)H:quinone reductase (DT-diaphorase) activity
24. Phenobarbital-induced cytosolic cytoprotective mechanisms that offset increases in NADPH cytochrome P450 reductase activity in menadione-mediated cytotoxicity
25. Disruption of the DT diaphorase (NQO1) gene in mice leads to increased menadione toxicity
26. Effect of inducers of DT-diaphorase on the toxicity of 2-methyl- and 2-hydroxy-1,4-naphthoquinone to rats
27. NAD(P)H:quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase
28. Bone marrow stromal cell bioactivation and detoxification of the benzene metabolite hydroquinone: Comparison of macrophages and fibroblastoid cells
29. Activation and deactivation of quinones catalyzed by DT-diaphorase. Evidence for bioreductive activation of diaziquone (AZQ) in human tumor cells and detoxification of benzene metabolites in bone marrow stroma
30. Cell-specific metabolism in mouse bone marrow stroma: Studies of activation and detoxification of benzene metabolites
31. Modulation of the toxicity and macromolecular binding of benzene metabolites by NAD(P)H:quinone oxidoreductase in transfected HL-60 cells
32. A potential mechanism underlying the increased susceptibility of individuals with a polymorphism in NAD(P)H:quinone oxidoreductase 1 (NQO1) to benzene toxicity
33. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems
34. DT-Diaphorase maintains the reduced state of ubiquinones in lipid vesicles thereby promoting their antioxidant function
35. Inhibition of lipid peroxidation by α-tocopherolquinone and α-tocopherolhydroquinone
36. Reduction of alpha-tocopherolquinone to alpha-tocopherol hydroquinone in rat hepatocytes
37. Is alpha-tocopherol a reservoir for alpha-tocopheryl hydroquinone?
38. The reduction of alpha-tocopherolquinone by human NAD(P)H:quinone oxidoreductase: The role of alpha-tocopherolhydroquinone as a cellular antioxidant
39. Pro- and antioxidant functions of quinones and quinone reductases in mammalian cells
40. Redox cycles of vitamin E: Hydrolysis and ascorbic acid dependent reduction of 8a-alkyldioxytocopherones
41. Immunodetection of NAD(P)H:quinone oxidoreductase 1 (NQO1) in human tissues
42. Immunohistochemical staining for NAD(P)H:quinone oxidoreductase (NQO1) in normal lung and lung tumors
43. Cytosolic NAD(P)H:quinone acceptor oxidoreductase in human normal and tumor tissue: Effects of cigarette smoking and alcohol
44. The metabolism of 4-nitroquinoline-1-oxide, a carcinogen by an enzyme catalyzing the conversion of 4-nitroquinoline-1-oxide to 4-hydroxylaminoquinoline-1-oxide in rat liver and hepatomas
45. Conversion of 4-nitroquinoline 1-oxide (4NQO) to 4-hydroxyaminoquinoline 1-oxide by a dicumarol-resistant hepatic 4NQO nitroreductase in rats and mice
46. Purified NAD(P)H-quinone oxidoreductase enhances the mutagenicity of dinitropyrenes in vitro
47. Therapeutic attack of hypoxic cells of solid tumors: Presidential address
48. Enzymology of bioreductive drug activation
49. Mechanisms of action of quinone-containing alkylating agents: NAO1-directed drug development
50. Gene targeting of DT-diaphorase in mouse embryonic stem cells: Establishment of null mutant and its mitomycin C-resistance
51. Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents
52. Expression of human NQO1 (DT-diaphorase) in Chinese hamster ovary cells: Effect on the toxicity of antitumor quinones
53. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines
54. A new screening system for NAD(P)H:quinone oxidoreductase(NQO1)-directed antitumor quinones: Identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent
55. Indolequinone antitumor agents: Relationship between quinone structure and rate of metabolism by recombinant human NQO1
56. Bioreductive activation of a series of indolequinones by human DT-diaphorase: Structure-activity relationships
57. The case for mitomycin in non-small cell lung cancer
58. Bioreductive activation of mitomycin C by DT-diaphorase
59. Nicotinamide adenine dinucleotide (phosphate):quinone oxidoreductase (DT-diaphorase) as a target for bioreductive antitumor quinones: Quinone cytotoxicity and selectivity in human lung and breast cancer cell lines
60. Metabolism of bioreductive antitumor compounds by purified rat and human DT-diaphorases
61. Indolequinone antitumor agents: Correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity
62. Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1. 6. 99. 2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): Implications for bioreductive drug development
63. Indolequinone antitumor agents: Reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro
64. Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4,7-dione] prop-β-en-α-ol (EO9) by human DT-diaphorase
65. Cyclopropamitosenes, novel bioreductive anticancer agents. Synthesis, electrochemistry, and biological activity of 7-substituted cyclopropamitosenes and related indolequinones
66. 2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: Structure-activity in vitro and efficacy in vivo
67. 5-Substituted analogues of 3-hydroxymethyl-5-aziridinyl-1-methyl-2-[1H-indole-4,7-dione]prop -2-en-1-ol (EO9, NSC 382459) and their regioisomers as hypoxia-selective agents: Structure-cytotoxicity in vitro
68. Phase II and pharmacokinetic study of aziridinylbenzoquinone [2, 5-diaziridinyl-3,6-bis(carboethoxyamino)-1,4-benzoquinone, diaziquone, NSC 182986] in high-grade gliomas
69. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity
70. Alteration in DNA cross-linking and sequence selectivity of a series of aziridinylbenzoquinones after enzymatic reduction by DT-diaphorase
71. Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice
72. Development and validation of a sensitive solid phase extraction and HPLC assay for RH1 in human and mouse plasma
73. Pyrrolo[1,2-a]benzimidazole-based aziridinyl quinones. A new class of DNA cleaving agent exhibiting G and A base specificity
74. Evidence for DNA phosphate backbone alkylation and cleavage by pyrrolo[1,2-a]benzimidazoles: Small molecules capable of causing base-pair-specific phosphodiester bond hydrolysis
75. Studies of pyrrolo[1,2-a]benzimidazolequinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation
76. Design of highly active analogues of the pyrrolo[1,2-a]benzimidazole antitumor agents
77. Novel quinolinequinone antitumor agents: Structure-metabolism studies with NAD(P)H:quinone oxidoreductase (NQO1)
78. Structural modification of model bioreductive antitumor agents: Effects on DT-diaphorase dependent bioreduction and cytotoxicity
79. Mechanisms of benzene carcinogenesis: Application of a physiological model of benzene pharmacokinetics and metabolism
80. 2,4-Dinitro-5-ethyleneiminobenzamide (CB 1954): A potent and selective inhibitor of the growth of the Walker carcinoma 256
81. A new cytotoxic DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells
82. Role of redox cycling and activation by DT-diaphorase in the cytotoxicity of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB-1954) and its analogs
83. Phthalimide analogs of CB 1954: Synthesis and bioactivation
84. Glutathione S-transferase π facilitates the excretion of arsenic from arsenic-resistant Chinese hamster ovary cells
85. Enzymology of tirapazamine metabolism: A review
86. DT-Diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90
87. Human dioxin inducible cytosolic NAD(P)H:menadione oxidoreductase
88. NAD(P)H:menadione oxidoreductase. Novel purification of enzyme, cDNA and complete amino acid sequence and gene regulation
89. Mouse dioxin-inducible NAD(P)H:menadione oxidoreductase: NMO1 cDNA sequence and genetic differences in mRNA levels
90. Human NAD(P)H:quinone oxidoreductase (NQO1) gene structure and induction by dioxin
91. A refined physical map of the long arm of human chromosome 16
92. Marked increases in hepatic NAD(P)H:oxidoreductase gene transcription and mRNA levels correlated with a mouse chromosome 7 deletion
93. Organization and characterization of the murine dioxin-inducible NAD(P)H:menadione oxidoreductase (NMO1) gene
94. Rat liver NAD(P)H:quinone reductase
95. Rat liver NAD(P)H:quinone reductase nucleotide sequence analysis of a quinone reductase cDNA clone and prediction of the amino acid sequence of the corresponding protein
96. Regulation and function of NAD(P)H:quinone oxidoreductase (NQO1)
97. The role of specific reductases in the intracellular activation and binding of 2-nitroimidazoles
98. Increase of NAD(P)H:quinone reductase by dietary antioxidants. Possible role in protection against carcinogenesis and toxicity
99. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis
100. Mechanisms of induction of NAD(P)H:quinone reductase
101. Induction of NAD(P)H:quinone reductase in murine hepatoma cells by phenolic antioxidants, azo dyes and other chemoprotectors: A model system for the study of anticarcinogens
102. Human antioxidant response element mediated regulation of type 1 NAD(P)H:quinone oxidoreductase gene expression
103. Antioxidant response element
104. Chemical and molecular regulation of enzymes that detoxify carcinogens
105. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements
106. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals
107. p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens
108. Regulation of c-jun expression during hypoxic and low-glucose stress
109. The genomic response of tumor cells to hypoxia and reoxygenation. Differential activation of transcription factors AP-1 and NF-kappa B
110. Hypoxia induces c-fos transcription via a mitogen-activated protein kinase-dependent pathway
111. The redox-sensitive human antioxidant responsive element induces gene expression under low oxygen conditions
112. Functional antioxidant responsive elements
113. Antitumor promotion by phenolic antioxidants: Inhibition of AP-1 activity through induction of Fra expression
114. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene
115. Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes
116. Activation of antioxidant/electrophile-responsive elements in IMR-32 human neuroblastoma cells
117. DT-diaphorase activity in NSCLC and SCLC cell lines: A role for fos/jun regulation
118. Disruption of c-Fos leads to increased expression of NAD(P)H:quinone oxidoreductase 1 and glutathione S-transferase
119. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites
120. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions
121. Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta
122. Detection of a nuclear protein which binds specifically to the antioxidant responsive element (ARE) of the human NAD(P)H:quinone oxidoreductase gene
123. The Ah receptor and the mechanism of dioxin toxicity
124. Regulation of the mammalian cytochrome P1-450 (CYP1A1) gene
125. Genetic differences in induction of cytosol reduced-NAD(P):menadione oxidoreductase and microsomal aryl hydrocarbon hydroxylase in the mouse
126. Role of cytochrome P1-450 in the induction of NAD(P)H:quinone reductase in a murine hepatoma cell line and its mutants
127. Transcriptional regulation of the rat glutathione S-transferase Ya subunit gene
128. Antioxidant response element-mediated 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) induction of human NAD(P)H:quinone oxidoreductase 1 gene expression
129. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: Characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity
130. Characterization of a polymorphism in NAD(P)H:Quinone oxidoreductase (DT-diaphorase)
131. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1
132. Catalytic properties of a naturally occurring mutant of human NAD(P)H:quinone oxidoreductase (DT-diaphorase), Pro 187 to Ser
133. Transfection of COS-1 cells with DT-diaphorase cDNA: Role of a base change at position 609
134. The NQO1*2 polymorphism in NAD(P)H:quinone oxidoreductase 1 targets the protein for proteasomal degradation
135. Ethnic variation in the prevalence of a common NAD(P)H:quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy
136. NAD(P)H:quinone oxidoreductase; polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations
137. NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells
138. The NAD(P)H:quinoneoxidoreductase locus in human colon carcinoma HCT 116 cells resistant to mitomycin C
139. Increased frequency of a null allele for NAD(P)H:quinone oxidoreductase in patients with urological malignancies
140. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:Quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia
141. Association of NAD(P)H:quinone oxidoreductase (NQO1) null with numbers of basal cell carcinomas: Use of a multivariate model to rank the relative importance of this polymorphism and those at other relevant loci
142. A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators
143. 609C→T mutation and rapid fractional excretion of chlorzoxazone
144. 609C→T polymorphism in NAD(P)H:quinone oxidoreductase gene in patients with prostatic adenocarcinoma or benign prostatic hyperplasia
145. Lung cancer in Mexican-Americans and African-Americans is associated with the wild type genotype of the NAD(P)H:quinone oxidoreductase polymorphism
146. Association of the NAD(P)H:quinone oxidoreductase 609C→T polymorphism with a decreased lung cancer risk
147. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase
148. Genetic polymorphism of NAD(P)H:quinone oxidoreductase and mitomycin C sensitivity in gastric cancer
149. Biochemical modulation of mitomycin C by induction of NADP(H):quinone oxidoreductase 1
150. Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells
151. A new screening system for NAD(P)H:quinone oxidoreductase(NQO1)-directed antitumor quinones. Identification of a new aziridinylbenzoquinone, RH1, as a NQO1-directed antitumor agent
152. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric carcinoma cell lines